世界の転移性悪性黒色腫治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Metastatic Malignant Melanoma Therapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A15030 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、転移性悪性黒色腫治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。転移性悪性黒色腫治療の種類別市場規模（免疫療法、標的療法、その他）、用途別市場規模（病院、医学研究機関、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・転移性悪性黒色腫治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Merck、Pfizer、Janssen Biotech、Roche、Navidea、Novartis、Bristol-Myers Squibb、Enzon Pharmaceuticals、Exelixis、GlaxoSmithKline、Ono Pharmaceutical、Amgen ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：免疫療法、標的療法、その他 ・用途別分析2016年-2026年：病院、医学研究機関、その他 ・転移性悪性黒色腫治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・転移性悪性黒色腫治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・転移性悪性黒色腫治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・転移性悪性黒色腫治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・転移性悪性黒色腫治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Metastatic Malignant Melanoma Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Metastatic Malignant Melanoma Therapy size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Metastatic Malignant Melanoma Therapy market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Metastatic Malignant Melanoma Therapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Immunotherapy
Targeted Therapy
Other

Market segment by Application, can be divided into
Hospital
Medical Research Organization
Other

Market segment by players, this report covers
Merck
Pfizer
Janssen Biotech
Roche
Navidea
Novartis
Bristol-Myers Squibb
Enzon Pharmaceuticals
Exelixis
GlaxoSmithKline
Ono Pharmaceutical
Amgen

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Metastatic Malignant Melanoma Therapy
1.2 Classification of Metastatic Malignant Melanoma Therapy by Type
1.2.1 Overview: Global Metastatic Malignant Melanoma Therapy Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Type in 2020
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.2.5 Other
1.3 Global Metastatic Malignant Melanoma Therapy Market by Application
1.3.1 Overview: Global Metastatic Malignant Melanoma Therapy Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Medical Research Organization
1.3.4 Other
1.4 Global Metastatic Malignant Melanoma Therapy Market Size & Forecast
1.5 Global Metastatic Malignant Melanoma Therapy Market Size and Forecast by Region
1.5.1 Global Metastatic Malignant Melanoma Therapy Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Metastatic Malignant Melanoma Therapy Market Size by Region, (2016-2021)
1.5.3 North America Metastatic Malignant Melanoma Therapy Market Size and Prospect (2016-2026)
1.5.4 Europe Metastatic Malignant Melanoma Therapy Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Metastatic Malignant Melanoma Therapy Market Size and Prospect (2016-2026)
1.5.6 South America Metastatic Malignant Melanoma Therapy Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Metastatic Malignant Melanoma Therapy Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Metastatic Malignant Melanoma Therapy Market Drivers
1.6.2 Metastatic Malignant Melanoma Therapy Market Restraints
1.6.3 Metastatic Malignant Melanoma Therapy Trends Analysis
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Metastatic Malignant Melanoma Therapy Product and Solutions
2.1.4 Merck Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Merck Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Metastatic Malignant Melanoma Therapy Product and Solutions
2.2.4 Pfizer Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Janssen Biotech
2.3.1 Janssen Biotech Details
2.3.2 Janssen Biotech Major Business
2.3.3 Janssen Biotech Metastatic Malignant Melanoma Therapy Product and Solutions
2.3.4 Janssen Biotech Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Janssen Biotech Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Metastatic Malignant Melanoma Therapy Product and Solutions
2.4.4 Roche Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Roche Recent Developments and Future Plans
2.5 Navidea
2.5.1 Navidea Details
2.5.2 Navidea Major Business
2.5.3 Navidea Metastatic Malignant Melanoma Therapy Product and Solutions
2.5.4 Navidea Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Navidea Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Metastatic Malignant Melanoma Therapy Product and Solutions
2.6.4 Novartis Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Bristol-Myers Squibb
2.7.1 Bristol-Myers Squibb Details
2.7.2 Bristol-Myers Squibb Major Business
2.7.3 Bristol-Myers Squibb Metastatic Malignant Melanoma Therapy Product and Solutions
2.7.4 Bristol-Myers Squibb Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.8 Enzon Pharmaceuticals
2.8.1 Enzon Pharmaceuticals Details
2.8.2 Enzon Pharmaceuticals Major Business
2.8.3 Enzon Pharmaceuticals Metastatic Malignant Melanoma Therapy Product and Solutions
2.8.4 Enzon Pharmaceuticals Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Enzon Pharmaceuticals Recent Developments and Future Plans
2.9 Exelixis
2.9.1 Exelixis Details
2.9.2 Exelixis Major Business
2.9.3 Exelixis Metastatic Malignant Melanoma Therapy Product and Solutions
2.9.4 Exelixis Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Exelixis Recent Developments and Future Plans
2.10 GlaxoSmithKline
2.10.1 GlaxoSmithKline Details
2.10.2 GlaxoSmithKline Major Business
2.10.3 GlaxoSmithKline Metastatic Malignant Melanoma Therapy Product and Solutions
2.10.4 GlaxoSmithKline Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 GlaxoSmithKline Recent Developments and Future Plans
2.11 Ono Pharmaceutical
2.11.1 Ono Pharmaceutical Details
2.11.2 Ono Pharmaceutical Major Business
2.11.3 Ono Pharmaceutical Metastatic Malignant Melanoma Therapy Product and Solutions
2.11.4 Ono Pharmaceutical Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Ono Pharmaceutical Recent Developments and Future Plans
2.12 Amgen
2.12.1 Amgen Details
2.12.2 Amgen Major Business
2.12.3 Amgen Metastatic Malignant Melanoma Therapy Product and Solutions
2.12.4 Amgen Metastatic Malignant Melanoma Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Amgen Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Metastatic Malignant Melanoma Therapy Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Metastatic Malignant Melanoma Therapy Players Market Share
3.2.2 Top 10 Metastatic Malignant Melanoma Therapy Players Market Share
3.2.3 Market Competition Trend
3.3 Metastatic Malignant Melanoma Therapy Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Metastatic Malignant Melanoma Therapy Revenue and Market Share by Type (2016-2021)
4.2 Global Metastatic Malignant Melanoma Therapy Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Application (2016-2021)
5.2 Metastatic Malignant Melanoma Therapy Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2026)
6.2 North America Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2026)
6.3 North America Metastatic Malignant Melanoma Therapy Market Size by Country
6.3.1 North America Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2026)
6.3.2 United States Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
6.3.3 Canada Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
6.3.4 Mexico Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2026)
7.2 Europe Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2026)
7.3 Europe Metastatic Malignant Melanoma Therapy Market Size by Country
7.3.1 Europe Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2026)
7.3.2 Germany Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
7.3.3 France Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
7.3.5 Russia Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
7.3.6 Italy Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2026)
8.2 Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2026)
8.3 Asia-Pacific Metastatic Malignant Melanoma Therapy Market Size by Region
8.3.1 Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Region (2016-2026)
8.3.2 China Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8.3.3 Japan Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8.3.4 South Korea Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8.3.5 India Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
8.3.7 Australia Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2026)
9.2 South America Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2026)
9.3 South America Metastatic Malignant Melanoma Therapy Market Size by Country
9.3.1 South America Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2026)
9.3.2 Brazil Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
9.3.3 Argentina Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2026)
10.2 Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2026)
10.3 Middle East & Africa Metastatic Malignant Melanoma Therapy Market Size by Country
10.3.1 Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2026)
10.3.2 Turkey Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
10.3.4 UAE Metastatic Malignant Melanoma Therapy Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Metastatic Malignant Melanoma Therapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Metastatic Malignant Melanoma Therapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Metastatic Malignant Melanoma Therapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Metastatic Malignant Melanoma Therapy Revenue (USD Million) by Region (2016-2021)
Table 5. Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Region (2021-2026)
Table 6. Merck Corporate Information, Head Office, and Major Competitors
Table 7. Merck Major Business
Table 8. Merck Metastatic Malignant Melanoma Therapy Product and Solutions
Table 9. Merck Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Metastatic Malignant Melanoma Therapy Product and Solutions
Table 13. Pfizer Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Janssen Biotech Corporate Information, Head Office, and Major Competitors
Table 15. Janssen Biotech Major Business
Table 16. Janssen Biotech Metastatic Malignant Melanoma Therapy Product and Solutions
Table 17. Janssen Biotech Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Roche Corporate Information, Head Office, and Major Competitors
Table 19. Roche Major Business
Table 20. Roche Metastatic Malignant Melanoma Therapy Product and Solutions
Table 21. Roche Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Navidea Corporate Information, Head Office, and Major Competitors
Table 23. Navidea Major Business
Table 24. Navidea Metastatic Malignant Melanoma Therapy Product and Solutions
Table 25. Navidea Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Metastatic Malignant Melanoma Therapy Product and Solutions
Table 29. Novartis Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 31. Bristol-Myers Squibb Major Business
Table 32. Bristol-Myers Squibb Metastatic Malignant Melanoma Therapy Product and Solutions
Table 33. Bristol-Myers Squibb Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Enzon Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Enzon Pharmaceuticals Major Business
Table 36. Enzon Pharmaceuticals Metastatic Malignant Melanoma Therapy Product and Solutions
Table 37. Enzon Pharmaceuticals Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Exelixis Corporate Information, Head Office, and Major Competitors
Table 39. Exelixis Major Business
Table 40. Exelixis Metastatic Malignant Melanoma Therapy Product and Solutions
Table 41. Exelixis Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 43. GlaxoSmithKline Major Business
Table 44. GlaxoSmithKline Metastatic Malignant Melanoma Therapy Product and Solutions
Table 45. GlaxoSmithKline Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Ono Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 47. Ono Pharmaceutical Major Business
Table 48. Ono Pharmaceutical Metastatic Malignant Melanoma Therapy Product and Solutions
Table 49. Ono Pharmaceutical Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Amgen Corporate Information, Head Office, and Major Competitors
Table 51. Amgen Major Business
Table 52. Amgen Metastatic Malignant Melanoma Therapy Product and Solutions
Table 53. Amgen Metastatic Malignant Melanoma Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Metastatic Malignant Melanoma Therapy Revenue (USD Million) by Players (2019-2021)
Table 55. Global Metastatic Malignant Melanoma Therapy Revenue Share by Players (2019-2021)
Table 56. Breakdown of Metastatic Malignant Melanoma Therapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Metastatic Malignant Melanoma Therapy Players Head Office, Products and Services Provided
Table 58. Metastatic Malignant Melanoma Therapy Mergers & Acquisitions in the Past Five Years
Table 59. Metastatic Malignant Melanoma Therapy New Entrants and Expansion Plans
Table 60. Global Metastatic Malignant Melanoma Therapy Revenue (USD Million) by Type (2016-2021)
Table 61. Global Metastatic Malignant Melanoma Therapy Revenue Share by Type (2016-2021)
Table 62. Global Metastatic Malignant Melanoma Therapy Revenue Forecast by Type (2021-2026)
Table 63. Global Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021)
Table 64. Global Metastatic Malignant Melanoma Therapy Revenue Forecast by Application (2021-2026)
Table 65. North America Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Metastatic Malignant Melanoma Therapy Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Metastatic Malignant Melanoma Therapy Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Metastatic Malignant Melanoma Therapy Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Metastatic Malignant Melanoma Therapy Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Metastatic Malignant Melanoma Therapy Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Metastatic Malignant Melanoma Therapy Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Metastatic Malignant Melanoma Therapy Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Metastatic Malignant Melanoma Therapy Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Metastatic Malignant Melanoma Therapy Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Metastatic Malignant Melanoma Therapy Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Metastatic Malignant Melanoma Therapy Picture
Figure 2. Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Type in 2020
Figure 3. Immunotherapy
Figure 4. Targeted Therapy
Figure 5. Other
Figure 6. Metastatic Malignant Melanoma Therapy Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Medical Research Organization Picture
Figure 9. Other Picture
Figure 10. Global Metastatic Malignant Melanoma Therapy Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Metastatic Malignant Melanoma Therapy Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Region (2016-2026)
Figure 13. Global Metastatic Malignant Melanoma Therapy Revenue Market Share by Region in 2020
Figure 14. North America Metastatic Malignant Melanoma Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Metastatic Malignant Melanoma Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Metastatic Malignant Melanoma Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Metastatic Malignant Melanoma Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Metastatic Malignant Melanoma Therapy Market Drivers
Figure 20. Metastatic Malignant Melanoma Therapy Market Restraints
Figure 21. Metastatic Malignant Melanoma Therapy Market Trends
Figure 22. Merck Recent Developments and Future Plans
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Janssen Biotech Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. Navidea Recent Developments and Future Plans
Figure 27. Novartis Recent Developments and Future Plans
Figure 28. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 29. Enzon Pharmaceuticals Recent Developments and Future Plans
Figure 30. Exelixis Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Ono Pharmaceutical Recent Developments and Future Plans
Figure 33. Amgen Recent Developments and Future Plans
Figure 34. Global Metastatic Malignant Melanoma Therapy Revenue Share by Players in 2020
Figure 35. Metastatic Malignant Melanoma Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Metastatic Malignant Melanoma Therapy Revenue Market Share in 2020
Figure 37. Global Top 10 Players Metastatic Malignant Melanoma Therapy Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Metastatic Malignant Melanoma Therapy Revenue Share by Type in 2020
Figure 40. Global Metastatic Malignant Melanoma Therapy Market Share Forecast by Type (2021-2026)
Figure 41. Global Metastatic Malignant Melanoma Therapy Revenue Share by Application in 2020
Figure 42. Global Metastatic Malignant Melanoma Therapy Market Share Forecast by Application (2021-2026)
Figure 43. North America Metastatic Malignant Melanoma Therapy Sales Market Share by Type (2016-2026)
Figure 44. North America Metastatic Malignant Melanoma Therapy Sales Market Share by Application (2016-2026)
Figure 45. North America Metastatic Malignant Melanoma Therapy Revenue Market Share by Country (2016-2026)
Figure 46. United States Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Metastatic Malignant Melanoma Therapy Sales Market Share by Type (2016-2026)
Figure 50. Europe Metastatic Malignant Melanoma Therapy Sales Market Share by Application (2016-2026)
Figure 51. Europe Metastatic Malignant Melanoma Therapy Revenue Market Share by Country (2016-2026)
Figure 52. Germany Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Metastatic Malignant Melanoma Therapy Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Metastatic Malignant Melanoma Therapy Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Metastatic Malignant Melanoma Therapy Revenue Market Share by Region (2016-2026)
Figure 60. China Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Metastatic Malignant Melanoma Therapy Sales Market Share by Type (2016-2026)
Figure 67. South America Metastatic Malignant Melanoma Therapy Sales Market Share by Application (2016-2026)
Figure 68. South America Metastatic Malignant Melanoma Therapy Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Metastatic Malignant Melanoma Therapy Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Metastatic Malignant Melanoma Therapy Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Metastatic Malignant Melanoma Therapy Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Metastatic Malignant Melanoma Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source

---